DK1228039T3 - N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater, der omfatter dem - Google Patents

N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater, der omfatter dem

Info

Publication number
DK1228039T3
DK1228039T3 DK00971396T DK00971396T DK1228039T3 DK 1228039 T3 DK1228039 T3 DK 1228039T3 DK 00971396 T DK00971396 T DK 00971396T DK 00971396 T DK00971396 T DK 00971396T DK 1228039 T3 DK1228039 T3 DK 1228039T3
Authority
DK
Denmark
Prior art keywords
guanidinoalkylamides
preparation
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
DK00971396T
Other languages
English (en)
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Armin Walser
James Ostrem
Fahad Al-Obeidi
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK1228039T3 publication Critical patent/DK1228039T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
DK00971396T 1999-10-30 2000-10-21 N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater, der omfatter dem DK1228039T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (en) 1999-10-30 1999-10-30 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
PCT/EP2000/010395 WO2001032611A1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (1)

Publication Number Publication Date
DK1228039T3 true DK1228039T3 (da) 2004-08-16

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00971396T DK1228039T3 (da) 1999-10-30 2000-10-21 N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater, der omfatter dem

Country Status (32)

Country Link
US (2) US6472562B1 (da)
EP (2) EP1095933A1 (da)
JP (1) JP4658430B2 (da)
KR (1) KR100981593B1 (da)
CN (1) CN1249026C (da)
AR (1) AR026257A1 (da)
AT (1) ATE264837T1 (da)
AU (1) AU776797B2 (da)
BR (1) BR0015186A (da)
CA (1) CA2389412C (da)
CZ (1) CZ301855B6 (da)
DE (1) DE60010113T2 (da)
DK (1) DK1228039T3 (da)
EE (1) EE05168B1 (da)
ES (1) ES2220553T3 (da)
HK (1) HK1050673A1 (da)
HR (1) HRP20020372B1 (da)
HU (1) HUP0203627A3 (da)
IL (2) IL149209A0 (da)
ME (1) MEP54708A (da)
MX (1) MXPA02003805A (da)
NO (1) NO328016B1 (da)
NZ (1) NZ518607A (da)
PL (1) PL203859B1 (da)
PT (1) PT1228039E (da)
RS (1) RS50471B (da)
RU (1) RU2253651C2 (da)
SI (1) SI1228039T1 (da)
SK (1) SK286856B6 (da)
TR (1) TR200201181T2 (da)
WO (1) WO2001032611A1 (da)
ZA (1) ZA200203294B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579240B2 (ja) * 2003-07-04 2010-11-10 ロンザ アーゲー 担持相合成法の改善
HUE052423T2 (hu) 2007-09-28 2021-04-28 Alexion Pharma Inc Az XA faktor inhibitorok antidótumai és ezek alkalmazási módszerei
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
WO2010117729A1 (en) 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) * 2021-05-10 2022-11-11 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经***疾病或心血管***疾病的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
JPH08506225A (ja) 1993-01-20 1996-07-02 ジョン アリグザンドロビクス，ピーター ラインモニタシステム
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
ES2214500T3 (es) 1994-04-26 2004-09-16 Aventis Pharmaceuticals, Inc. Inhibidores de factor xa.
TW300888B (da) * 1994-12-02 1997-03-21 Yamanouchi Pharma Co Ltd
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
KR20010023364A (ko) * 1997-08-27 2001-03-26 간자와 무츠와 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
ES2241194T3 (es) 1997-12-24 2005-10-16 Aventis Pharma Deutschland Gmbh Derivados de indol en calidad de inhibidores de factor xa.
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1176958B1 (en) * 1999-05-05 2004-07-28 Merck & Co., Inc. Novel catechols as antimicrobial agents

Also Published As

Publication number Publication date
HRP20020372B1 (en) 2011-01-31
CA2389412C (en) 2009-12-01
MXPA02003805A (es) 2004-10-15
ATE264837T1 (de) 2004-05-15
TR200201181T2 (tr) 2002-09-23
BR0015186A (pt) 2002-07-23
CZ20021489A3 (cs) 2002-07-17
SK286856B6 (sk) 2009-06-05
DE60010113T2 (de) 2005-05-04
AU1026501A (en) 2001-05-14
JP2003513066A (ja) 2003-04-08
ZA200203294B (en) 2003-01-29
HUP0203627A3 (en) 2004-12-28
US20030162967A1 (en) 2003-08-28
US6472562B1 (en) 2002-10-29
YU29702A (sh) 2005-06-10
HRP20020372A2 (en) 2004-08-31
US6664393B2 (en) 2003-12-16
HUP0203627A2 (hu) 2003-03-28
PL354808A1 (en) 2004-02-23
RS50471B (sr) 2010-03-02
KR20020047310A (ko) 2002-06-21
EE05168B1 (et) 2009-06-15
NZ518607A (en) 2003-10-31
EP1228039A1 (en) 2002-08-07
HK1050673A1 (en) 2003-07-04
EP1095933A1 (en) 2001-05-02
CN1249026C (zh) 2006-04-05
AU776797B2 (en) 2004-09-23
RU2002114041A (ru) 2004-01-20
IL149209A0 (en) 2002-11-10
PT1228039E (pt) 2004-09-30
NO20022022D0 (no) 2002-04-29
KR100981593B1 (ko) 2010-09-13
SK5782002A3 (en) 2002-10-08
NO328016B1 (no) 2009-11-09
ES2220553T3 (es) 2004-12-16
CZ301855B6 (cs) 2010-07-14
NO20022022L (no) 2002-04-29
CA2389412A1 (en) 2001-05-10
RU2253651C2 (ru) 2005-06-10
SI1228039T1 (en) 2004-10-31
AR026257A1 (es) 2003-02-05
IL149209A (en) 2007-06-03
DE60010113D1 (de) 2004-05-27
CN1387508A (zh) 2002-12-25
PL203859B1 (pl) 2009-11-30
EP1228039B1 (en) 2004-04-21
MEP54708A (en) 2011-05-10
EE200200199A (et) 2003-06-16
WO2001032611A1 (en) 2001-05-10
JP4658430B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
DK1095016T3 (da) Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
NO20014013D0 (no) 16-halogenepotilonderivater, fremgangsmater for fremstilling av dem og deres farmasoytiske anvendelse
DK1337529T3 (da) Heterocyclylalkylpiperidinderivater, deres fremstilling og præparater indeholdende dem
NO20015156L (no) 5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
NO20014603D0 (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
DK1083171T3 (da) Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20016038D0 (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20014702D0 (no) Diarylderivater og deres anvendelse som medikamenter
DK1370550T3 (da) Quinolylpropylpiperidinderivater, deres fremstilling og præparater indeholdende dem
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1095020T3 (da) 2-Aminopyridinderivater, deres anvendelse som lægemidler og farmaceutiske præparater, der indeholder dem
DK1183256T3 (da) Puridinderivater, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
NO20023146L (no) Substituerte fenyl-piperazinderivater, deres fremstilling og anvendelse
DK1228039T3 (da) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater, der omfatter dem
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20014803D0 (no) Pyrido-tieno-diazepiner, fremgangsmåte for fremstilling derav og farmasöytiske blandinger inneholdende dem
NO20024354L (no) N-deacetyltiocolchicin-derivater og farmasöytiske sammensetninger inneholdende dem
DK1149832T3 (da) Benzamidderivater og lægemidler, der indeholder dem
DK1341753T3 (da) Cyclohexyl (alkyl) -propanolaminer, deres fremstilling, og farmaceutiske sammensætninger, der indeholder dem
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse